When you have asthma, the airways in your lungs get narrow and swollen. They also make too much mucus. This sets off spasms in the tubes that let air in and out of your lungs (bronchial tubes). The ...

Specific sputum markers, including higher sputum eosinophils, macrophages, and lymphocyte counts, were associated with remission after interleukin-5 (IL-5)–targeted therapy for patients with severe ...

Regular asthma reviews are required all year round, not just in the winter months. FeNO testing is an excellent way to ...

Please provide your email address to receive an email when new articles are posted on . There were no significant differences in the incidence of the first exacerbation event between the biologics.

Discover a study exploring how high serum TSLP influences adult asthma and implications for targeted treatment.

Eosinophil White Blood Cell What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma? Mepolizumab and benralizumab ...

What can you do to help your eosinophilic asthma treatments work their best? There are simple steps you can take each day to improve symptoms, quality of life, and overall health. Eosinophilic asthma ...

AstraZeneca is partnering with actor and asthma sufferer Tony Hale to raise awareness about a severe type of asthma—and promote the drugmaker's free blood test to diagnose the condition. The “Veep” ...

Please provide your email address to receive an email when new articles are posted on . Benralizumab reduced levels of IgE circulating in the blood among patients with severe eosinophilic asthma but ...

AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...

AstraZeneca has imagined a swarm of annoying anthropomorphized eosinophils—a type of white blood cell that causes airway inflammation and asthma symptoms—mucking around and ruining everything in their ...

Initial Series A raise of $350 million funding Areteia Phase III development program of dexpramipexole in eosinophilic asthma, including three ongoing Phase III clinical trials Additional funding of ...